Terns Pharmaceuticals Inc (TERN) - Total Assets
Based on the latest financial reports, Terns Pharmaceuticals Inc (TERN) holds total assets worth $301.65 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Terns Pharmaceuticals Inc book value and equity for net asset value and shareholders' equity analysis.
Terns Pharmaceuticals Inc - Total Assets Trend (2018–2024)
This chart illustrates how Terns Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Terns Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Terns Pharmaceuticals Inc's total assets of $301.65 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Terns Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Terns Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Terns Pharmaceuticals Inc's current assets represent 99.5% of total assets in 2024, an increase from 99.3% in 2018.
- Cash Position: Cash and equivalents constituted 44.4% of total assets in 2024, down from 92.7% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Terns Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Terns Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Terns Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.52 | 32.99 | 3.98 |
| Quick Ratio | 19.52 | 32.99 | 3.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $284.91 Million | $365.09 Million | $68.05 Million |
Terns Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Terns Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.47 |
| Latest Market Cap to Assets Ratio | 11.29 |
| Asset Growth Rate (YoY) | 35.5% |
| Total Assets | $363.93 Million |
| Market Capitalization | $4.11 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Terns Pharmaceuticals Inc's assets at a significant premium (11.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Terns Pharmaceuticals Inc's assets grew by 35.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual total assets of Terns Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $363.93 Million | +35.53% |
| 2023-12-31 | $268.52 Million | -6.45% |
| 2022-12-31 | $287.03 Million | +70.78% |
| 2021-12-31 | $168.07 Million | +82.11% |
| 2020-12-31 | $92.29 Million | +286.09% |
| 2019-12-31 | $23.90 Million | -73.16% |
| 2018-12-31 | $89.07 Million | -- |
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more